Natco Erlotinib Price India | Erlonat Erlotinib 100mg Tablets

About Erlonat Erlotinib 100mg Tablets

Erlotinib is also known by its brand name, Erlonat . It is a treatment for
• Pancreatic cancer that has spread – alongside the another chemotherapy drug
• Non small cell lung cancer that has spread
image
Brand Name : Erlonat
Active Ingredients : Erlotinib Hydrochloride
Manufactured by: Natco Pharma Ltd.
Strength: 100 mg
Form: Tablets
Packing: Pack of 30 Tablets

What are the possible Side Effects of Erlotinib?

Erlotinib can cause serious side effects, including:
Lung problems : Symptoms of lung problems may include shortness of breath, cough, and fever. Erlotinib may need to be stopped if you have any of these symptoms
Liver and kidney problems. Some people had their kidneys and liver stop working. Speak your doctor know if you have a history of liver or kidney disease
Stomach and intestinal problems (called gastrointestinal [GI] perforation). A GI perforation is a hole that develops in your stomach or intestine.
Serious skin conditions. Erlotinib has been shown to cause blistering and skin peeling. This may result in other serious skin disorders or death
Blood, bleeding, and clotting problems. Erlonat has been shown to cause certain blood problems and other bleeding and clotting problems. These have led to stroke and death.
Eye disorders. It has been shown to cause dry eyes, unusual eyelash growth, or swelling of the cornea. The cornea is the clear coating of the eyeball. This swelling may irritate or damage the eye
Pregnancy. Erlotinib can harm an unborn baby. Tell your doctor if you have become pregnant, or if you think you may be pregnant, during treatment with it. Do not breast-feed during treatment with it.

What should I know about skin (including rash), hair, and nail problems or diarrhea while taking Erlotinib?

Skin (including rash): While taking Erlotinib, rash could happen or get worse if the skin is exposed to the sun. You may want to use alcohol-free lotions and sunscreens or avoid being out in the sun
Your skin and nails may get darker. You may also have dry skin that may or may not crack. This most often happens with rash
Talk with your doctor if you notice a rash. He or she may be able to help you manage it
Hair and nails: Hair and nail problems have been seen in patients taking Erlotinib. These include increased hairiness and brittle or loose nails
Diarrhea: Diarrhea can usually be treated with antidiarrhea medicine. Your Health Care Provider can help you find the right medicine for you

What should I do if I am taking or am prescribed other medicines or supplements while taking Erlotinib?

• Always tell your doctor about all of the medicines and herbal supplements you are taking
• Do not start taking any new medicines or herbal supplements before talking with your doctor
• Do not eat grapefruit or drink grapefruit juice .

Will smoking affect my treatment with Erlotinib?

• If you smoke, you should stop smoking before you start treatment with Erlotinib
• If you continue to smoke, your treatment with Erlotinib may need to be adjusted. Talk with your doctor if you continue to smoke
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

Source:http://www.bagtheweb.com/b/9Oi8l3

Comments

  1. UnknownDecember 18, 2018 at 5:04 PM

    Erlonat 150mg Tablet. is a kinase inhibitor which is primarily used to treat cell lung cancer.Erlonat Tablet works by inhibiting growth to adjacent tissues in the body so that the cancerous cells slow down, allowing the patient a better environment to recover and fight cancer naturally.

    ReplyDelete
  2. EmimadiJuly 12, 2019 at 11:55 AM

    this article is very useful for me to know about Erlonat 100mg,Erlonat 100mg tablets details...,
    thank you for sharing this article..,
    Erlonat 100mg
    Erlonat 100mg tablets

    ReplyDelete

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more